Compare Global X FTSE Southeast Asia ETF (ASEA) vs AstraZeneca plc (AZN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Global X FTSE Southeast Asia ETF vs AstraZeneca plc — how do they compare? Global X FTSE Southeast Asia ETF trades at $20.65, while AstraZeneca plc trades at $169.63 (market cap $262.75B). The key difference: AstraZeneca plc pays a 1.84% dividend while Global X FTSE Southeast Asia ETF pays none, and Global X FTSE Southeast Asia ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| ASEA | AZN | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $20.65 | $209.48 |
52-Week Low | $16.31 | $137.44 |
Market Cap | — | $262.75B |
Enterprise Value | — | $289.00B |
Dividend Yield | — | 1.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ASEA stock trades at $20.65, up 0.63% today, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong momentum with an ADX of 49.11 indicating a trending market. Recent corporate actions include a declared dividend of $0.41 per share scheduled for July 2026. Key support and resistance levels are clustered around $20-$21, suggesting a critical price zone for near-term direction.
The outlook remains cautiously optimistic given technical strength, but fundamental data is currently unavailable for a complete assessment. Risks include potential volatility near key technical levels and reliance on future financial performance disclosures. Investors should await upcoming earnings reports for clarity on valuation and profitability metrics.
AstraZeneca (AZN) trades at $171.61, down 3.85% following a Phase 3 clinical trial failure for its Wainua heart drug. The stock faces bearish technical signals with support at $167 and resistance at $177. Fundamentally, the company maintains strong profitability with 17.19% net margins and robust revenue growth, reaching $58.74B in 2025. Analyst consensus remains positive with 47.5% buy ratings despite recent setbacks.
The outlook remains cautiously optimistic as AstraZeneca's core business fundamentals remain intact with improving cash flow and debt reduction. However, pipeline execution risks and clinical trial uncertainties present near-term headwinds. Long-term investors may find value at current levels given the company's strong market position and financial health.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X FTSE Southeast Asia ETF
ASEA tracks the performance of the largest companies in Southeast Asia. It provides exposure to key emerging markets including Singapore, Indonesia, Thailand, and Malaysia, with a heavy focus on financials like DBS Group and Bank Central Asia.
Read more on ASEA →About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →
